Moderna Inc.

79.83+2.13+2.74%Vol 3.85M1Y Perf -57.19%
Dec 1st, 2023 16:00 DELAYED
BID79.52 ASK80.25
Open76.58 Previous Close77.70
Pre-Market- After-Market79.67
 - -  -0.16 -0.20%
Target Price
221.58 
Analyst Rating
Moderate Buy 2.39
Potential %
177.57 
Finscreener Ranking
★★★★★     59.51
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     60.30
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     86.07
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
11.17 
Earnings Rating
Strong Sell
Market Cap30.44B 
Earnings Date
2nd Nov 2023
Alpha0.04 Standard Deviation0.27
Beta1.70 

Today's Price Range

74.5080.26

52W Range

62.55217.25

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.04%
1 Month
1.97%
3 Months
-30.97%
6 Months
-39.54%
1 Year
-57.19%
3 Years
-44.90%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
MRNA79.832.13002.74
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
Financial StrengthValueIndustryS&P 500US Markets
1.60
2.10
0.05
0.07
534.20
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
78.50
64.60
66.30
-257.00
50.25
RevenueValueIndustryS&P 500US Markets
13.73B
35.73
490.66
237.86
Earnings HistoryEstimateReportedSurprise %
Q03 2023-2.01-1.3930.85
Q02 2023-3.84-3.625.73
Q01 2023-1.770.19110.73
Q04 20224.663.61-22.53
Q03 20223.042.53-16.78
Q02 20224.505.2416.44
Q01 20225.188.5865.64
Q04 20219.8311.2914.85
Earnings Per EndEstimateRevision %Trend
12/2023 QR-1.23-659.09Negative
12/2023 FY-5.94-41.77Negative
3/2024 QR-2.6010.34Positive
12/2024 FY-6.65-20.04Negative
Next Report Date-
Estimated EPS Next Report-1.98
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume3.85M
Shares Outstanding381.28K
Shares Float321.42M
Trades Count58.71K
Dollar Volume302.20M
Avg. Volume3.59M
Avg. Weekly Volume2.58M
Avg. Monthly Volume4.23M
Avg. Quarterly Volume3.95M

Moderna Inc. (NASDAQ: MRNA) stock closed at 77.7 per share at the end of the most recent trading day (a -1.66% change compared to the prior day closing price) with a volume of 3.24M shares and market capitalization of 30.44B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1300 people. Moderna Inc. CEO is Stephane Bancel.

The one-year performance of Moderna Inc. stock is -57.19%, while year-to-date (YTD) performance is -56.74%. MRNA stock has a five-year performance of %. Its 52-week range is between 62.55 and 217.25, which gives MRNA stock a 52-week price range ratio of 11.17%

Moderna Inc. currently has a PE ratio of 3.30, a price-to-book (PB) ratio of 3.85, a price-to-sale (PS) ratio of 5.15, a price to cashflow ratio of 11.50, a PEG ratio of 0.49, a ROA of 50.09%, a ROC of 77.98% and a ROE of 83.69%. The company’s profit margin is 50.25%, its EBITDA margin is 66.30%, and its revenue ttm is $13.73 Billion , which makes it $35.73 revenue per share.

Of the last four earnings reports from Moderna Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.98 for the next earnings report. Moderna Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Moderna Inc. is Moderate Buy (2.39), with a target price of $221.58, which is +177.57% compared to the current price. The earnings rating for Moderna Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Moderna Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Moderna Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.14, ATR14 : 3.59, CCI20 : 76.66, Chaikin Money Flow : 0.25, MACD : -1.64, Money Flow Index : 47.44, ROC : 10.92, RSI : 46.79, STOCH (14,3) : 74.67, STOCH RSI : 0.29, UO : 51.85, Williams %R : -25.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Moderna Inc. in the last 12-months were: AFEYAN NOUBAR (Sold 165 000 shares of value $18 233 563 ), Arpa Garay (Option Excercise at a value of $0), Bancel Stephane (Option Excercise at a value of $1 531 683), Bancel Stephane (Option Exercise at a value of $26 883), Bancel Stephane (Sold 1 574 310 shares of value $219 185 506 ), Berenson Stephen (Option Excercise at a value of $0), Hoge Stephen (Option Excercise at a value of $0), Hoge Stephen (Sold 34 497 shares of value $4 171 764 ), James Mock (Sold 0 shares of value $0 ), James Mock (Sold 2 858 shares of value $292 945 ), Juan Andres (Option Excercise at a value of $167 440), Juan Andres (Sold 8 000 shares of value $1 497 720 ), Klinger Shannon (Option Excercise at a value of $0), Klinger Shannon (Sold 1 695 shares of value $226 455 ), Klinger Shannon Thyme (Sold 110 shares of value $14 336 ), Shannon Thyme Klinger (Option Excercise at a value of $0), Shannon Thyme Klinger (Sold 1 510 shares of value $229 794 ), Stephane Bancel (Option Excercise at a value of $1 306 800), Stephane Bancel (Sold 1 370 000 shares of value $237 716 464 ), Stephen Hoge (Option Excercise at a value of $0), Stephen Hoge (Sold 1 317 shares of value $188 119 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (38.89 %)
6 (37.50 %)
6 (37.50 %)
Moderate Buy
1 (5.56 %)
1 (6.25 %)
1 (6.25 %)
Hold
8 (44.44 %)
8 (50.00 %)
8 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (11.11 %)
1 (6.25 %)
1 (6.25 %)
Summary RatingModerate Buy
2.39
Moderate Buy
2.31
Moderate Buy
2.31

Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

CEO: Stephane Bancel

Telephone: +1 617 714-6500

Address: 200 Technology Square, Cambridge 02139, MA, US

Number of employees: 1 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

49%51%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

 

TipRanks News for MRNA

Tue, 21 Nov 2023 16:06 GMT Moderna tells Reuters will appeal European Patent Office decision

- TipRanks. All rights reserved.

Fri, 03 Nov 2023 09:01 GMT Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Moderna (MRNA) and Regeneron (REGN)

- TipRanks. All rights reserved.

Thu, 02 Nov 2023 14:06 GMT Moderna (MRNA) Receives a Buy from UBS

- TipRanks. All rights reserved.

Tue, 22 Aug 2023 13:55 GMT Early notable gainers among liquid option names on August 22nd

- TipRanks. All rights reserved.

News

Stocktwits